OBJECTIVE
To assess the efficacy and safety of botulinum toxin type A (BoNT-A; BOTOX, Allergan, Inc., Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH) without the confounding factor of concurrent prophylactic medications.
BACKGROUND
Several open-label studies and an 11-month, randomized, double-blind, placebo-controlled study suggest that BoNT-A may b...